JP3615496B2 - １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシレート塩・３水和物を製造するための方法 - Google Patents

１−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシレート塩・３水和物を製造するための方法 Download PDF

Info

Publication number
JP3615496B2
JP3615496B2 JP2001124290A JP2001124290A JP3615496B2 JP 3615496 B2 JP3615496 B2 JP 3615496B2 JP 2001124290 A JP2001124290 A JP 2001124290A JP 2001124290 A JP2001124290 A JP 2001124290A JP 3615496 B2 JP3615496 B2 JP 3615496B2
Authority
JP
Japan
Prior art keywords
formula
hydroxyphenyl
propanol
hydroxy
phenylpiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001124290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001354651A (ja
Inventor
ジョセフ・フィリップ・レインヴィル
テリー・ジーン・シネイ，ジュニアー
スタンリー・ウォルター・ウォリンスキー
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2001354651A publication Critical patent/JP2001354651A/ja
Application granted granted Critical
Publication of JP3615496B2 publication Critical patent/JP3615496B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
JP2001124290A 2000-04-28 2001-04-23 １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシレート塩・３水和物を製造するための方法 Expired - Fee Related JP3615496B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20067300P 2000-04-28 2000-04-28
US60/200673 2000-04-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004071015A Division JP2004196823A (ja) 2000-04-28 2004-03-12 １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシレート・３水和物塩の光学活性化合物

Publications (2)

Publication Number Publication Date
JP2001354651A JP2001354651A (ja) 2001-12-25
JP3615496B2 true JP3615496B2 (ja) 2005-02-02

Family

ID=22742684

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001124290A Expired - Fee Related JP3615496B2 (ja) 2000-04-28 2001-04-23 １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシレート塩・３水和物を製造するための方法
JP2004071015A Pending JP2004196823A (ja) 2000-04-28 2004-03-12 １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシレート・３水和物塩の光学活性化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004071015A Pending JP2004196823A (ja) 2000-04-28 2004-03-12 １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシレート・３水和物塩の光学活性化合物

Country Status (27)

Country Link
US (1) US6645986B2 (US06573293-20030603-C00009.png)
EP (2) EP1477479A1 (US06573293-20030603-C00009.png)
JP (2) JP3615496B2 (US06573293-20030603-C00009.png)
KR (1) KR100442718B1 (US06573293-20030603-C00009.png)
CN (2) CN1590373A (US06573293-20030603-C00009.png)
AR (1) AR028376A1 (US06573293-20030603-C00009.png)
AT (1) ATE277014T1 (US06573293-20030603-C00009.png)
AU (1) AU781436B2 (US06573293-20030603-C00009.png)
BR (1) BR0101630A (US06573293-20030603-C00009.png)
CA (1) CA2345582C (US06573293-20030603-C00009.png)
CZ (1) CZ20011471A3 (US06573293-20030603-C00009.png)
DE (1) DE60105689T2 (US06573293-20030603-C00009.png)
DK (1) DK1151995T3 (US06573293-20030603-C00009.png)
ES (1) ES2227071T3 (US06573293-20030603-C00009.png)
HK (1) HK1040246B (US06573293-20030603-C00009.png)
HU (1) HUP0101723A3 (US06573293-20030603-C00009.png)
ID (1) ID30006A (US06573293-20030603-C00009.png)
IL (1) IL142705A0 (US06573293-20030603-C00009.png)
IN (1) IN191027B (US06573293-20030603-C00009.png)
PL (1) PL347298A1 (US06573293-20030603-C00009.png)
PT (1) PT1151995E (US06573293-20030603-C00009.png)
RU (1) RU2203888C2 (US06573293-20030603-C00009.png)
SI (1) SI1151995T1 (US06573293-20030603-C00009.png)
TR (1) TR200402696T4 (US06573293-20030603-C00009.png)
TW (1) TW200505858A (US06573293-20030603-C00009.png)
YU (1) YU27701A (US06573293-20030603-C00009.png)
ZA (1) ZA200103320B (US06573293-20030603-C00009.png)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098765A1 (en) * 2000-06-21 2001-12-27 Bioarray Solutions, Ltd. Multianalyte molecular analysis
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
CN1930304B (zh) * 2003-11-21 2016-01-06 Anp技术公司 不对称支化的聚合物缀合物和微阵列检测
DE602006019709D1 (US06573293-20030603-C00009.png) 2005-05-02 2011-03-03 Anp Technologies Inc

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0843661T3 (da) * 1995-08-11 2002-07-22 Pfizer (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat

Also Published As

Publication number Publication date
AU3889601A (en) 2001-11-01
JP2001354651A (ja) 2001-12-25
PT1151995E (pt) 2004-11-30
DE60105689D1 (de) 2004-10-28
EP1151995B1 (en) 2004-09-22
BR0101630A (pt) 2001-12-04
AU781436B2 (en) 2005-05-26
ES2227071T3 (es) 2005-04-01
CN1321638A (zh) 2001-11-14
ATE277014T1 (de) 2004-10-15
HUP0101723A3 (en) 2003-03-28
ID30006A (id) 2001-11-01
PL347298A1 (en) 2001-11-05
YU27701A (sh) 2003-04-30
IN191027B (US06573293-20030603-C00009.png) 2003-09-13
CZ20011471A3 (cs) 2002-02-13
DK1151995T3 (da) 2004-12-13
AR028376A1 (es) 2003-05-07
CA2345582A1 (en) 2001-10-28
TW200505858A (en) 2005-02-16
HK1040246B (zh) 2005-10-28
JP2004196823A (ja) 2004-07-15
CN1210262C (zh) 2005-07-13
RU2203888C2 (ru) 2003-05-10
EP1151995A1 (en) 2001-11-07
KR20010098960A (ko) 2001-11-08
IL142705A0 (en) 2002-03-10
CN1590373A (zh) 2005-03-09
HU0101723D0 (en) 2001-07-30
HK1040246A1 (en) 2002-05-31
US6645986B2 (en) 2003-11-11
EP1477479A1 (en) 2004-11-17
SI1151995T1 (en) 2004-12-31
ZA200103320B (en) 2002-10-24
KR100442718B1 (ko) 2004-08-02
US20020016465A1 (en) 2002-02-07
TR200402696T4 (tr) 2004-11-22
CA2345582C (en) 2006-05-30
DE60105689T2 (de) 2005-11-10
HUP0101723A2 (hu) 2002-02-28

Similar Documents

Publication Publication Date Title
EP0843661B1 (en) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate
JP2610784B2 (ja) フェノールアルカノールアミノ誘導体
JP3615496B2 (ja) １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシレート塩・３水和物を製造するための方法
US5852040A (en) Neuroprotective 3,4-dihydro-2(1H)-quinolone compounds
KR100432841B1 (ko) 1-(4-히드록시페닐)-2-(4-히드록시-4-페닐피페리딘-1-일)-1-프로판올의 메실레이트염 삼수화물의 제조 방법 및 이에유용한 중간체
MXPA01004288A (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)- 2-(4-hydroxy-4- phenylpiperidin-1-yl)- 1-propanol
MXPA01004289A (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl) -2-(4-hydroxy-4- phenylpiperidin -1-yl) -1-propanol and intermediates useful therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040312

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20040415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20041005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20041029

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees